Value of GastroPanel in the diagnosis of atrophic gastritis

Grad, Cosmin; Pop, Andrei V.; Gaborean, Emil; Grad, Simona; Dumitraşcu, Dan L.

doi:10.3892/etm.2021.10782

Cited by 10 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some previous studies, based on Biohit's claims, the GastroPanel kit has been proposed as a non-invasive method for diagnosing gastric atrophy, as well as various degrees of atrophy. 10,[14][15][16] Nevertheless, there is some controversy about this issue, 17 and the results of the present study did not confirm this assumption.…”

Section: Discussioncontrasting

confidence: 85%

Value of Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection

Sivandzadeh

Fard²,

Zahmatkesh

et al. 2023

Middle East J Dig Dis

View full text Add to dashboard Cite

Background: Gastric cancer is one of the most common types of cancer worldwide. Helicobacter pylori infection is clearly correlated with gastric carcinogenesis. Therefore, the use of a new non-invasive test, known as the GastroPanel test, can be very helpful to identify patients at a high risk, including those with atrophic gastritis, intestinal metaplasia, and dysplasia. This study aimed to compare the results of GastroPanel test with the pathological findings of patients with gastric atrophy to find a safe and simple alternative for endoscopy and biopsy as invasive methods.Methods: This cross-sectional study was performed on patients with indigestion, who were referred to Motahari Clinic and Shahid Faghihi Hospital of Shiraz, Iran, since April 2017 until August 2017 for endoscopy of the upper gastrointestinal tract. The serum levels of gastrin-17 (G17), pepsinogen I (PGI), and pepsinogen II (PGII), as well as H. pylori antibody IgG, were determined by ELISA assays. Two biopsy specimens from the antrum and gastric body were taken for standard histological analyses and rapid urease test. A pathologist examined the biopsy specimens of patients blindly. Results: A total of 153 patients with indigestion (62.7% female; mean age, 63.7 years; 37.3% male; mean age, 64.9 years) were included in this study. The G17 levels significantly increased in patients with chronic atrophic gastritis (CAG) of the body (9.7 vs. 32.8 pmol/L; P = 0.04) and reduced in patients with antral CAG (1.8 vs. 29.1 pmol/L; P = 0.01). The results were acceptable for all three types of CAG, including the antral, body, and multifocal CAG (AUCs of 97%, 91%, and 88% for body, antral, and multifocal CAG, respectively). The difference in PGII level was not significant. Also, the PGI and PGI/PGII ratio did not show a significant difference (unacceptably low AUCs for all). The H. pylori antibody levels were higher in patients infected with H. pylori (251 EIU vs. 109 EIU, AUC = 70, P = 0.01). There was a significant relationship between antibody tests and histopathology.Conclusion: Contrary to Biohit’s claims, the GastroPanel kit is not accurate enough to detect CAG; therefore, it cannot be used for establishing a clinical diagnosis.

show abstract

Section: Discussioncontrasting

confidence: 85%

Value of Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection

Sivandzadeh

Fard²,

Zahmatkesh

et al. 2023

Middle East J Dig Dis

View full text Add to dashboard Cite

show abstract

“…The GastroPanel test is widely used for risk stratification 18 ; nonetheless, there are concerns regarding I/II ratios. Recent studies reported that I/II ratios did not correlate with the severity or location of atrophy when using the GastroPanel test 19,20 . Another study concluded that the GastroPanel test is insufficient for cancer screening because only 32.4% of gastric cancer patients showed low I/II ratios of <3 21 .…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies reported that I/II ratios did not correlate with the severity or location of atrophy when using the GastroPanel test. 19,20 Another study concluded that the GastroPanel test is insufficient for cancer screening because only 32.4% of gastric cancer patients showed low I/II ratios of <3. 21 In our study, low I/II ratios and high G-17 levels correlated well with atrophy and IM scores according to the Kyoto classification.…”

Section: Discussionmentioning

confidence: 99%

Comparison between the GastroPanel test and the serum pepsinogen assay interpreted with the ABC method—A prospective study

Lee,

Ahn,

Moon

2024

Helicobacter

View full text Add to dashboard Cite

Background and AimsThis study aimed to validate Helicobacter pylori serological and pepsinogen (PG) assays for detecting infection and gastric neoplasm.MethodsIndividuals who underwent serum Chorus H. pylori and HBI PG assays were included from May to September 2023. The GastroPanel test was performed using the same blood sample. HBI assay findings were interpreted with the ABC method using the criteria of corpus atrophy (PG I ≤ 70 ng/mL & I/II ≤3) and advanced corpus atrophy (PG I ≤ 30 ng/mL & I/II ≤2).ResultsA total of 144 H. pylori‐infected and 184 non‐infected Koreans were analyzed. The Chorus test (sensitivity 97.2%, specificity 89.1%) showed higher area under the curve (0.993 vs. 0.972, p = 0.003) than the GastroPanel test (sensitivity 95.8%, specificity 86.4%). Using the GastroSoft application, the incidence of gastric neoplasms was highest in the corpus atrophy group (50%), followed by the low acid‐output (25.8%), H. pylori infection (11.6%), and antral atrophy (9.1%) groups. There were no gastric neoplasms in the normal and high acid output groups. Using the ABC method, the incidence of gastric neoplasms was highest in the corpus atrophy groups (23.8% in Groups C and D), followed by Group B (12.3%) and Group A (2.4%). Corpus atrophy interpreted with the GastroSoft showed poor agreement (k = 0.225) with corpus atrophy interpreted with the ABC method, whereas it showed excellent agreement (k = 0.854) with advanced corpus atrophy.ConclusionsAlthough the Chorus test was more accurate than the GastroPanel test, both assays discriminated high‐risk individuals by detecting atrophy or infection. There were no gastric neoplasms in the normal or high acid‐output groups (GastroSoft application), and gastric neoplasm incidence was lowest in Group A (ABC method). Corpus atrophy determined by GastroSoft application is more consistent with advanced corpus atrophy determined by the ABC method than is corpus atrophy.

show abstract

“…New evidence has been published for the diagnostic performance indices of GP for both AG and HP infection. [29][30][31][32]…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

“…To our knowledge, there are no meta-analyses on diagnostic accuracy of GP for HP infection. New evidence has been published for the diagnostic performance indices of GP for both AG and HP infection 29–32…”

Section: Introductionmentioning

confidence: 99%

Panel of serum biomarkers (GastroPanel) in diagnosis of atrophic gastritis and Helicobacter pylori infection: a protocol of systematic review and meta-analysis

Wu¹,

Shi

Wang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

IntroductionThe aetiology of gastric cancer is still unclear but Helicobacter pylori (HP) infection and chronic atrophic gastritis (AG) are recognised as two major risk factors for gastric cancer. GastroPanel (GP) test is the first non-invasive diagnostic tool to detect AG and HP infection.The aim of the study is to conduct a systematic review and meta-analysis to review published literature about the GP test for diagnosing AG and HP infection, with the objective of estimating the diagnostic performance indices of GP for AG and HP infection.Methods and analysisThis protocol of systematic review and meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement guidelines. PubMed, Embase, Web of Science and Cochrane Library databases will be systematically searched from inception to March 2022 for eligible studies. No language limitations were imposed. The studies will be downloaded into the EndNote V.X9 software and duplicates will be removed. Two review authors independently screened the full text against the inclusion criteria, extracted the data from each included study by using a piloted data extraction form and conducted risk of bias assessment, resolving disagreement by discussion. Results will be synthesised narratively in summary tables, using a random-effect bivariate model, and we fit a hierarchical summary receiver operating characteristic curve.Ethics and disseminationThis systematic review will include data extracted form published studies, therefore, does not require ethics approval. The results of this study will be submitted to a peer-reviewed journal.PROSPERO registration numberCRD42021282616.

show abstract

Value of GastroPanel in the diagnosis of atrophic gastritis

Cited by 10 publications

References 27 publications

Value of Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection

Value of Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection

Comparison between the GastroPanel test and the serum pepsinogen assay interpreted with the ABC method—A prospective study

Panel of serum biomarkers (GastroPanel) in diagnosis of atrophic gastritis and Helicobacter pylori infection: a protocol of systematic review and meta-analysis

Contact Info

Product

Resources

About